Datar Cancer Genetics Unveils Exacta AI: A Revolutionary AI-Driven Cancer Treatment Platform

Metropolis Healthcare Partners with Roche to Launch Self-Sampling HPV DNA Test for Cervical Cancer Screening in India

Union Budget 2025: Full Exemption from Basic Customs Duty (BCD) for 36 Lifesaving Drugs

Dr. Jitendra Singh Inaugurates Centre for Advanced Genomics & Precision Medicine at AIIMS Jammu

Union Budget 2025-26: Key Healthcare Measures for Cancer Care and Access to Life-Saving Drugs

FDA Approves Roche’s PATHWAY HER2 Test for Identifying HER2-Ultralow Breast Cancer Patients Eligible for ENHERTU

Bristol Myers Squibb’s Breyanzi® Receives CHMP Recommendation for Relapsed or Refractory Follicular Lymphoma in the EU

NHS to Offer Groundbreaking Gene Therapy for Sickle Cell Disease

Quibim Secures $50M Series A to Advance AI-Powered Imaging for Precision Medicine

Apollo Hospitals Unveils Advanced Oncology Facility in Chennai

Beckman Coulter’s Alzheimer’s Blood Test Receives FDA Breakthrough Device Designation

ANGLE Announces Breakthrough Dual CTC-DNA and ctDNA Analysis with Illumina’s NGS Solution

Diatech Pharmacogenetics and Merck Expand Collaboration to Enhance RAS Biomarker Testing in MEA Region

DCG Unveils AI-Powered Video-Reporting for Personalized Chemotherapy Selection

FDA Approves Monthly Maintenance Dosing for LEQEMBI® in Alzheimer’s Treatment

Home
/
update
/
details

Seegene and Springer Nature Forge Strategic Partnership

NextEdge Admin

16 May 2024

2 min 14 sec

Seegene , a leading South Korean PCR molecular diagnostics company, has entered a strategic alliance with Springer Nature, publisher of the prestigious journal, Nature. Aligned in their mission to advance scientific discovery and combat diseases, this alliance aims to accelerate PCR diagnostic testing across various disease areas.

The collaboration leverages the expertise of both parties to support global researchers. By utilizing the expansive network of Springer Nature, funding, and technology will be provided to scientists worldwide, enhancing the development of diagnostic products.

Building upon the success of their 2023 Open Innovation Program, which aimed to develop innovative diagnostic products, this initiative seeks to democratize early disease diagnosis. Through the OneSystem™ business model, potential partners will be identified and annual symposiums will be co-hosted.

Dr. Jong-Yoon Chun, CEO of Seegene, expressed enthusiasm for the alliance’s potential to advance their SG OneSystem™ business and achieve a disease-free world. Springer Nature’s CEO, Frank Vrancken Peeters, commended Seegene’s efforts and emphasized the importance of collaboration in achieving their shared goal.

The inaugural Open Innovation Program received significant global interest, resulting in 26 selected applicants from 47 countries. For 2024, the program adopts a more open format, encouraging applicants to propose diverse product developments.

Both companies anticipate that this collaboration will contribute to democratizing PCR molecular diagnostics, fostering an ecosystem of innovation to address unmet needs in global healthcare.